Rakovina Therapeutics Inc. RKV.V

RKV.V Company Overview

Rakovina Therapeutics Inc. is a Canadian biotechnology company focused on the discovery and development of cancer therapies targeting the DNA damage response (DDR) pathway. The company operates in the oncology and precision medicine sectors, with research centered on small-molecule inhibitors designed to improve outcomes in difficult-to-treat cancers. Rakovina’s programs have emphasized next-generation poly (ADP-ribose) polymerase (PARP) inhibitors and other DDR-related therapeutic candidates intended to address tumor resistance mechanisms and improve selectivity profiles relative to earlier therapies.

The company traces its origins to oncology-focused intellectual property and development programs associated with Canadian cancer research initiatives. Rakovina Therapeutics has evolved into a publicly traded life sciences company listed on the TSX Venture Exchange under the ticker RKV. Its strategic positioning is tied to early-stage oncology drug discovery, collaborations with academic and scientific institutions, and the application of computational and structure-guided drug design approaches to precision oncology. Public disclosures indicate that the company’s business model is primarily research-driven rather than commercial-stage pharmaceutical sales based.